Straits Times Index
3,265.95 +1.42 (+0.04%) S&P 500
5,214.08 +26.41 (+0.51%) Dow
39,387.76 +331.36 (+0.85%) Nasdaq
16,346.26 +43.46 (+0.27%) Bitcoin USD
62,890.48 +1,559.82 (+2.54%) CMC Crypto 200
1,352.21 +52.11 (+4.01%)
Eli Lilly and Company (LLY.DE)
| Previous close | 720.90 |
| Open | 720.10 |
| Bid | 720.10 x 0 |
| Ask | 720.70 x 0 |
| Day's range | 718.20 - 727.50 |
| 52-week range | 387.20 - 745.70 |
| Volume | |
| Avg. volume | 5,585 |
| Market cap | 682.798B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 113.31 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.83 (0.67%) |
| Ex-dividend date | 15 May 2024 |
| 1y target est | N/A |
- PR Newswire
Lilly Declares Second-Quarter 2024 Dividend
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common stock.
- PR Newswire
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2024.
- PR Newswire
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the sever
